GAITHERSBURG, Md. — February 12, 2026 — Leads & Copy —
Emergent BioSolutions (NYSE: EBS) announced today that the U.S. Food and Drug Administration (FDA) has approved its supplemental New Drug Application (sNDA) for new multipack configurations of over-the-counter (OTC) NARCAN® Nasal Spray. The approval will broaden the NARCAN® Nasal Spray portfolio and improve cost-effectiveness by increasing flexibility and distribution efficiency of this life-saving medication.
The approval expands the NARCAN® Nasal Spray product suite to include 6-count and 24-count multipack options, specifically designed to meet the needs of partners distributing higher volumes of naloxone. According to Emergent, these new formats offer enhanced flexibility with the same trusted product, benefiting community programs and organizations operating large-scale, multi-site, or high-volume distribution programs.
Paul Williams, senior vice president, head of products business, global government & public affairs at Emergent, said the introduction of NARCAN® Nasal Spray multipacks marks a significant step in empowering the company’s partners. Williams said Emergent works closely with its partners to develop solutions that help improve delivery, distribution, and accessibility of NARCAN® Nasal Spray. He added that partners can now better streamline bulk distribution, support broad preparedness efforts, and ultimately ensure that more communities and individuals have ready access to this life-saving medication in the event of an opioid overdose emergency.
The FDA approval builds on Emergent’s ongoing commitment to enhancing NARCAN® Nasal Spray accessibility and usability, complementing the recent FDA approval of the NARCAN® Nasal Spray Carrying Case in January 2026. These efforts underscore Emergent’s comprehensive approach to equipping individuals and organizations with effective tools to combat opioid overdose deaths.
The company said the 6-count and 24-count multipacks will soon be available to purchase for public interest customers through NARCANDirect®, Emergent’s proprietary ordering and distribution platform. Emergent added that the multipacks are an addition to the current portfolio and will not replace existing product formats. Since the prescription launch of NARCAN® Nasal Spray in 2016, more than 85 million doses have been distributed across the U.S. and Canada.
NARCAN® Naloxone HCl Nasal Spray 4 mg is the first FDA-approved, over-the-counter (OTC) 4 mg naloxone product for the emergency treatment of opioid overdose. NARCAN® Nasal Spray is not a substitute for emergency medical care, and repeat dosing may be necessary. Use as directed.
At Emergent, the company’s mission is to protect and save lives. For over 25 years, the company has been at work preparing those entrusted with protecting public health. Emergent delivers protective and life-saving solutions for health threats like smallpox, mpox, botulism, Ebola, anthrax, and opioid overdose emergencies.
Source: Emergent BioSolutions
